CN102417922A - Uricase method determination reagent for eliminating interference of ascorbic acid and use method thereof - Google Patents

Uricase method determination reagent for eliminating interference of ascorbic acid and use method thereof Download PDF

Info

Publication number
CN102417922A
CN102417922A CN2010105050348A CN201010505034A CN102417922A CN 102417922 A CN102417922 A CN 102417922A CN 2010105050348 A CN2010105050348 A CN 2010105050348A CN 201010505034 A CN201010505034 A CN 201010505034A CN 102417922 A CN102417922 A CN 102417922A
Authority
CN
China
Prior art keywords
reagent
sample
xitix
uric acid
interferential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010105050348A
Other languages
Chinese (zh)
Inventor
王浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Shiji Kangda Medical Equipment Co ltd
Original Assignee
Hangzhou Shiji Kangda Medical Equipment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Shiji Kangda Medical Equipment Co ltd filed Critical Hangzhou Shiji Kangda Medical Equipment Co ltd
Priority to CN2010105050348A priority Critical patent/CN102417922A/en
Publication of CN102417922A publication Critical patent/CN102417922A/en
Pending legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a uricase method determination reagent for eliminating interference of ascorbic acid (vitamin C, VC) and a using method thereof. The reagent is a liquid double reagent, and has good ascorbic acid interference performance and excellent stability. The two-point end point method can be used on a semi/full automatic biochemical analyzer. The product adopts a specific enzyme, so that the reagent has the characteristics of high sensitivity and strong anti-interference performance; the product is added with the selected stabilizer, so that the reagent has good stability, and the performance of the reagent is not influenced after the reagent is stored (sealed in a dark place) at the temperature of 2-8 ℃ for 12 months. The reagent can be widely used for diagnosing kidney diseases such as acute and chronic nephritis, kidney stone, gout and the like, and diseases such as leukemia, multiple myeloma and the like with excessive nucleic acid metabolism, health examination, general investigation of kidney diseases and the like.

Description

A kind of elimination xitix interferential uric acid enzymic measuring reagent and method of use thereof
Technical field
The invention belongs to biological technical field, relate to a kind of elimination xitix interferential uric acid enzymic measuring reagent and method of use thereof.
Background technology
Uric acid (UA) is the final product of purine metabolism in the nucleic acid, and in human body, purine nucleotides through hydrolytic deaminization and oxidation, generates UA after decomposing generation purine nucleoside and purine at last.UA discharges with urine, and UA all leaches through renal glomerulus in the blood, is almost completely heavily absorbed at uriniferous tubules, so the clearance rate of UA is extremely low.The UA that is discharged by kidney accounts for the 2/3-3/4 of total output on the one, and all the other are decomposed by the enzyme of mikrobe at gi tract.UA can not normally drain when GFR lowered, and UA concentration raises in the blood.Some medicines also influence the drainage of UA, can promote the discharge of UA like this semi-annular jade pendant of thiazide diuretic box hydroxyl amine.The Whitfield's ointment preparation also increases its drainage when high dosage.Usually the increase of UA level and nitrogenous substances, urea, creatinine are relevant with other non-albumen factors, are usually used in the not auxiliary diagnosis of the hyperuricemia of bright reason of gout, renal tubal dysfunction, bone marrow disease and some clinically.
Clinical meaning:
(1) content of the excretory function of the accretion rate of UA content and nucleic acid in vivo in blood, kidney and food amplifying nucleic acid is relevant.UA is difficult to dissolving, and concentration Gao Shihui is deposited in the tissue, forms calculus.
(2) serum UA once more is mainly seen in gout, is the leading indicator of clinical diagnosis gout.Due to the imbalance of uratoma purine metabolism, serum UA can obviously raise.
(3) the hyperfunction endogenous UA that causes of nucleic acid metabolism generates increase, and serum UA rises.Be shown in white blood disease, multiple myeloma, polycythemia vera etc.
(4) gestational hypertension, the pathology that renal blood flows such as eclampsia reduce raises serum UA because of UA drains to reduce.But the normal no change of SUR this moment.
(5) serum UA raises and also is shown in chronic lead poisoning, chloroform and carbon tetrachloride poisoning.
(6) the many because metabolism disorder of Hypouricemia generates not enough, uriniferous tubules like UA and the transhipment of UA is reached in the urine UA unusually discharges due to unusual the increasing, and also is shown in WilsonShi disease, Fancoi syndromes, serious anaemia etc.
Hyperuricemia has caused showing great attention to of medical circle as the sick new kind of modern civilization, detects UA exactly and in clinical application, more seems important.The UA measuring method is a lot, and phospho-wolframic acid method, uric acid enzyme process, dry chemistry method and HPLC method etc. are arranged.Present most popular method is uriKoxidase-peroxidase reaction system, method sensitive and do not need deproteinize, main obscurant be xitix (vitamins C, VC) and UCB.Therefore, solve the interference problem that xitix and UCB are measured UA, significant.
Summary of the invention
Technical problem to be solved by this invention provides a kind of immunity from interference good elimination xitix interferential uric acid enzymic measuring reagent and method of use thereof.
The present invention solves the problems of the technologies described above the technical scheme that is adopted: a kind of elimination xitix interferential uric acid enzymic measuring reagent, and said reagent is liquid double reagent, wherein a kind of component of reagent 1 and content are:
Phosphate buffered saline buffer (pH 6.0-8.0) 0.10-100g/L,
Px 0.10-10KU/L,
N-ethyl-N-(3-toluene)-N-succinyl-quadrol EMSE 0.10-10g/L,
Anti-interference enzyme 0.10-10KU/L,
Stablizer 0.10-100g/L;
Wherein the component of second kind of reagent 2 and content are:
Phosphate buffered saline buffer (pH 6.0-8.0) 0.10-100g/L,
Px 0.10-10KU/L,
UriKoxidase 0.10-10KU/L,
4-aminoantipyrene 4-AAP 0.10-10g/L,
Stablizer 0.10-100g/L.
Specifically, said anti-interference enzyme is a Vitamin C oxidase; Said stablizer is at least a in bovine serum albumin, yellow prussiate, Triton-100, polyvalent alcohol, the polyoxyethylene glycol; Wherein phosphate buffered saline buffer can adopt potassium hydrogenphosphate, potassium primary phosphate etc.
A kind of method of use of above-mentioned anti-VC interferential uric acid enzymic measuring reagent comprises the steps:
(1) sample is prepared: sample is not haemolysis serum or a blood plasma of empty stomach, and sample transports preservation under coldcondition;
(2) adopt automatic clinical chemistry analyzer that the sample of step (1) is detected, concrete parameter is following:
Reaction type: 2 end-point methods,
The Direction of Reaction: positive reaction,
Predominant wavelength: 600nm,
Commplementary wave length: 800nm,
Temperature of reaction: 37 ℃,
Sample/reagent (S/R): 3/200,
Sample size (S): 3 μ l,
Reagent 1 (R1): 150 μ l,
Reagent 2 (R2): 50 μ l,
Reaction times: 10min.
Insoluble blood serum of empty stomach or blood plasma adopt anticoagulant heparin in the step (1), but 0.1mg heparin anti-freezing 1.0ml blood; Or employing EDTA anti-freezing: but 1.8mg EDTA anti-freezing 1.0ml blood.Uric acid can be stablized 8 hours at ambient temperature in the sample, can stablize 3 days at 2 ℃～8 ℃, can stablize 6 months-20 ℃ of preservations.
In sum, the invention has the beneficial effects as follows: reagent of the present invention is liquid double reagent, has good anti-xitix (vitamins C, VC) jamming performance and advantages of excellent stability.Adopt 2 end-point methods, can on half/automatic clinical chemistry analyzer, use.These article have adopted a kind of specific enzyme, make reagent have characteristics highly sensitive, strong anti-interference performance; These article add selected stablizer, make reagent have satisfactory stability property, and preserving (lucifuge sealing) down at 2-8 ℃ did not influence its performance in 12 months.This reagent can be widely used in kidney diseases such as acute and chronic nephritis, urinary stone disease, gout, and the generaI investigation of the diagnosis of containing disease, health examination, kidney disease etc. is crossed in nucleic acid metabolisms such as white blood disease, multiple myeloma.
Embodiment
Embodiment 1:
(1) sample is prepared: sample is not haemolysis serum or blood plasma (anticoagulant heparin, but 0.1mg heparin anti-freezing 1.0ml blood of empty stomach; The EDTA anti-freezing: but 1.8mg EDTA anti-freezing 1.0ml blood).Sample should transport preservation under coldcondition, uric acid can be stablized 8 hours at ambient temperature in the sample, can stablize 3 days at 2 ℃～8 ℃, can stablize 6 months-20 ℃ of preservations.
(2) by following composition and consumption preparation testing uric acid reagent:
Reagent 1:
Phosphate buffered saline buffer (pH 6.0-8.0) 0.10-100g/L,
Px 0.10-10KU/L,
N-ethyl-N-(3-toluene)-N-succinyl-quadrol EMSE 0.10-10g/L,
Anti-interference enzyme 0.10-10KU/L,
Stablizer 0.10-100g/L;
Reagent 2:
Phosphate buffered saline buffer (pH 6.0-8.0) 0.10-100g/L,
Px 0.10-10KU/L,
UriKoxidase 0.10-10KU/L,
4-aminoantipyrene 4-AAP 0.10-10g/L,
Stablizer 0.10-100g/L.
Above-mentioned each component and content thereof are specially; Phosphate buffered saline buffer is the arbitrary value between the 0.10-100g/L in the reagent 1; Be specially 0.1,0.2,0.5,1,3,5,10,20,30,40,50,60,70,80,90,100g/L all can; PH is the arbitrary value between the 6.0-8.0, is specially 6,6.2,6.5,6.7,7.0,7.2,7.5,7.7,8.0 and all can; Px is the arbitrary value between the 0.10-10KU/L, is specially 0.1,0.2,0.5,0.8,1,3,5,7,10KU/L all can; N-ethyl-N-(3-toluene)-N-succinyl-quadrol EMSE is the arbitrary value between the 0.10-10g/L, is specially 0.1,0.3,0.5,1,3,5,10g/L all can; Anti-interference enzyme is the arbitrary value between the 0.10-10KU/L, is specially 0.1,0.2,0.5,0.8,1,3,5,7,10KU/L all can; Stablizer is the arbitrary value between the 0.10-100g/L, is specially 0.1,0.2,0.5,1,3,5,10,20,30,40,50,60,70,80,90,100g/L all can.Phosphate buffered saline buffer is the arbitrary value between the 0.10-100g/L in the reagent 2; Be specially 0.1,0.2,0.5,1,3,5,10,20,30,40,50,60,70,80,90,100g/L all can; PH is the arbitrary value between the 6.0-8.0, is specially 6,6.2,6.5,6.7,7.0,7.2,7.5,7.7,8.0 and all can; Px is the arbitrary value between the 0.10-10KU/L, is specially 0.1,0.2,0.5,0.8,1,3,5,7,10KU/L all can; UriKoxidase is the arbitrary value between the 0.10-10KU/L, is specially 0.1,0.2,0.5,0.8,1,3,5,7,10KU/L all can; The 4-aminoantipyrene is the arbitrary value between the 0.10-10g/L, is specially 0.1,0.3,0.5,1,3,5,10g/L all can; Stablizer is the arbitrary value between the 0.10-100g/L, is specially 0.1,0.2,0.5,1,3,5,10,20,30,40,50,60,70,80,90,100g/L all can.
After the mentioned reagent dissolving is accomplished, divide the bottle of packing into, process liquid double reagent, directly use.On the TBA-120FR of Toshiba type automatic clinical chemistry analyzer according to following parameter setting:
Reaction type: 2 end-point methods,
The Direction of Reaction: positive reaction,
Predominant wavelength: 600nm,
Commplementary wave length: 800nm,
Temperature of reaction: 37 ℃,
Sample/reagent (S/R): 3/200,
Sample size (S): 3 μ l,
Reagent 1 (R1): 150 μ l,
Reagent 2 (R2): 50 μ l,
Reaction times: 10min.
During mensuration, sample adds reagent 1 and is incubated 300 seconds down at 37 ℃, the record absorbance A 1, behind the adding reagent 2, be incubated 300 seconds down, the record absorbance A at 37 ℃ 2, calculate the sample uric acid concentration by following formula:
Below through the related experiment data to anti-VC interferential uric acid enzymic measuring reagent of the present invention, its beneficial effect is further specified, concrete experimental data is following:
1, anti-triglyceride disturbs (mg/dL)
(1) prior art single reagent (A reagent)
Figure BSA00000301151500041
(2) prior art double reagent (B reagent)
Figure BSA00000301151500042
(3) reagent of the present invention (C reagent)
Figure BSA00000301151500043
2, anti-hemolysis disturbs (mg/dL)
(1) prior art single reagent (A reagent)
Figure BSA00000301151500044
Figure BSA00000301151500051
(2) prior art double reagent (B reagent)
Figure BSA00000301151500052
(3) reagent of the present invention (C reagent)
Figure BSA00000301151500053
3, anti-UCB disturbs (mg/dL)
(1) prior art single reagent (A reagent)
Figure BSA00000301151500054
(2) prior art double reagent (B reagent)
Figure BSA00000301151500055
Figure BSA00000301151500061
(3) reagent of the present invention (C reagent)
Figure BSA00000301151500062
4, anti-VC disturbs (mg/dL)
(1) prior art single reagent (A reagent)
Figure BSA00000301151500063
(2) prior art double reagent (B reagent)
Figure BSA00000301151500064
(3) reagent of the present invention (C reagent)
Figure BSA00000301151500065
Figure BSA00000301151500071
5, uncork stability
Level one quality control product (low value): lot number, 567UN; Target value 340 μ mol/L, scope 300-390 μ mol/L;
Level two quality control products (high value): lot number, 413UE; Target value 560 μ mol/L, scope 490-630 μ mol/L.
Unit: μ mol/L
Figure BSA00000301151500072
Conclusion: uncork 30 days is measured result's the relative error of result and the 1st day all less than 10%, meets the requirement of standard.
The component and the content of prior art single reagent (A reagent) are:
Phosphate buffered saline buffer (pH 7.5) 100mmol/L,
Px 10KU/L,
DHBS 2.0mmol/L，
4-aminoantipyrene 4-AAP 4.0mmol/L,
UriKoxidase 150U/L.
The component and the content of prior art double reagent (B reagent) are:
Reagent 1:
Phosphate buffered saline buffer (pH 7.0) 100mmol/L,
TBHBA 1mmol/L；
Reagent 2:
Phosphate buffered saline buffer (pH 7.0) 100mmol/L,
4-aminoantipyrene 4-AAP 0.3mmol/L,
Px 2KU/L,
UriKoxidase 3U/L.
Experiment showed, that through above-mentioned reagent interference free performance of the present invention obviously is superior to the single reagent and the double reagent of prior art, have the interference effect of good anti-xitix (VC).

Claims (5)

  1. One kind eliminate xitix (vitamins C, VC) interferential uric acid enzymic measuring reagent and method of use thereof is characterized in that, said reagent is liquid double reagent, wherein the component of first kind of reagent 1 and content are:
    Phosphate buffered saline buffer (pH 6.0-8.0) 0.10-100g/L,
    Px 0.10-10KU/L,
    N-ethyl-N-(3-toluene)-N-succinyl-quadrol EMSE 0.10-10g/L,
    Anti-interference enzyme 0.10-10KU/L,
    Stablizer 0.10-100g/L;
    Wherein the component of second kind of reagent 2 and content are:
    Phosphate buffered saline buffer (pH 6.0-8.0) 0.10-100g/L,
    Px 0.10-10KU/L,
    UriKoxidase 0.10-10KU/L,
    4-aminoantipyrene 4-AAP 0.10-10g/L,
    Stablizer 0.10-100g/L.
  2. 2. elimination xitix interferential uric acid enzymic measuring reagent according to claim 1 is characterized in that said anti-interference enzyme is a Vitamin C oxidase, and content is 0.1-10KU/L.
  3. 3. elimination xitix interferential uric acid enzymic measuring reagent according to claim 1 is characterized in that, said stablizer is at least a in bovine serum albumin, yellow prussiate, Triton-100, polyvalent alcohol, the polyoxyethylene glycol.
  4. 4. the method for use of the described elimination xitix of claim 1 an interferential uric acid enzymic measuring reagent is characterized in that, comprises the steps:
    (1) sample is prepared: sample is not haemolysis serum or a blood plasma of empty stomach, and sample transports preservation under coldcondition;
    (2) adopt automatic clinical chemistry analyzer that the sample of step (1) is detected, concrete parameter is following:
    Reaction type: 2 end-point methods,
    The Direction of Reaction: positive reaction,
    Predominant wavelength: 600nm,
    Commplementary wave length: 800nm,
    Temperature of reaction: 37 ℃,
    Sample/reagent (S/R): 3/200,
    Sample size (S): 3 μ l,
    Reagent 1 (R1): 150 μ l,
    Reagent 2 (R2): 50 μ l,
    Reaction times: 10min.
  5. 5. according to the method for use of the said elimination xitix of claim 4 interferential uric acid enzymic measuring reagent, it is characterized in that said empty stomach is haemolysis serum or blood plasma employing anticoagulant heparin not, but 0.1mg heparin anti-freezing 1.0ml blood; Or employing EDTA anti-freezing: but 1.8mg EDTA anti-freezing 1.0ml blood.
CN2010105050348A 2010-09-25 2010-09-25 Uricase method determination reagent for eliminating interference of ascorbic acid and use method thereof Pending CN102417922A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010105050348A CN102417922A (en) 2010-09-25 2010-09-25 Uricase method determination reagent for eliminating interference of ascorbic acid and use method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010105050348A CN102417922A (en) 2010-09-25 2010-09-25 Uricase method determination reagent for eliminating interference of ascorbic acid and use method thereof

Publications (1)

Publication Number Publication Date
CN102417922A true CN102417922A (en) 2012-04-18

Family

ID=45942566

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010105050348A Pending CN102417922A (en) 2010-09-25 2010-09-25 Uricase method determination reagent for eliminating interference of ascorbic acid and use method thereof

Country Status (1)

Country Link
CN (1) CN102417922A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103278648A (en) * 2013-05-24 2013-09-04 宁波美康生物科技股份有限公司 Albumin detection reagent
CN103571916A (en) * 2013-11-22 2014-02-12 重庆医科大学 Formula of kit for testing content of uric acid through double reagent method
CN104198473A (en) * 2014-08-14 2014-12-10 上海睿康生物科技有限公司 Stable uric acid detection kit
CN106290323A (en) * 2015-06-04 2017-01-04 章丘美高义医疗器械有限公司 A kind of stable, uric acid reagent that capacity of resisting disturbance is strong and detection method
CN106404758A (en) * 2015-07-28 2017-02-15 珠海和凡医药股份有限公司 Test paper for detecting uric acid content range in urine
CN109187389A (en) * 2018-09-07 2019-01-11 大连大学 A kind of detection kit of marine low temperature urate oxidase measurement uric acid
CN109856128A (en) * 2018-12-24 2019-06-07 迪瑞医疗科技股份有限公司 A kind of urine glucose detection test paper and preparation method thereof of ascorbic acid interference
CN110951823A (en) * 2019-12-31 2020-04-03 扬中酵诚生物技术研究有限公司 Uric acid detection kit and manufacturing process thereof
CN113418916A (en) * 2021-07-02 2021-09-21 安徽惠邦生物工程有限公司 Creatinine quantitative rapid detection test strip and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
黄亨健等: "《抗坏血酸氧化酶在TRINDER反应中抗VC干扰应用评价》", 《华西医学》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103278648A (en) * 2013-05-24 2013-09-04 宁波美康生物科技股份有限公司 Albumin detection reagent
CN103278648B (en) * 2013-05-24 2015-01-21 宁波美康盛德医学检验所有限公司 Albumin detection reagent
CN103571916A (en) * 2013-11-22 2014-02-12 重庆医科大学 Formula of kit for testing content of uric acid through double reagent method
CN103571916B (en) * 2013-11-22 2016-03-16 重庆医科大学 A kind of double reagent method measures the formula of uric acid content test kit
CN104198473A (en) * 2014-08-14 2014-12-10 上海睿康生物科技有限公司 Stable uric acid detection kit
CN104198473B (en) * 2014-08-14 2017-07-07 上海睿康生物科技有限公司 A kind of uric acid detection kit of stabilization
CN106290323A (en) * 2015-06-04 2017-01-04 章丘美高义医疗器械有限公司 A kind of stable, uric acid reagent that capacity of resisting disturbance is strong and detection method
CN106404758A (en) * 2015-07-28 2017-02-15 珠海和凡医药股份有限公司 Test paper for detecting uric acid content range in urine
CN109187389A (en) * 2018-09-07 2019-01-11 大连大学 A kind of detection kit of marine low temperature urate oxidase measurement uric acid
CN109856128A (en) * 2018-12-24 2019-06-07 迪瑞医疗科技股份有限公司 A kind of urine glucose detection test paper and preparation method thereof of ascorbic acid interference
CN110951823A (en) * 2019-12-31 2020-04-03 扬中酵诚生物技术研究有限公司 Uric acid detection kit and manufacturing process thereof
CN113418916A (en) * 2021-07-02 2021-09-21 安徽惠邦生物工程有限公司 Creatinine quantitative rapid detection test strip and preparation method thereof

Similar Documents

Publication Publication Date Title
CN102417922A (en) Uricase method determination reagent for eliminating interference of ascorbic acid and use method thereof
Staufer et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease
den Bakker et al. Endogenous markers for kidney function in children: a review
EP2668497B1 (en) Urine biomarkers for prediction of recovery after acute kidney injury : proteomics
EP3712279B1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
Herget-Rosenthal et al. How to estimate GFR-serum creatinine, serum cystatin C or equations?
Lunn et al. Automated enzymatic assays for the determination of intestinal permeability probes in urine. 2. Mannitol
EP2601532B1 (en) Perlecan as a biomarker for renal dysfunction
Chou et al. TSG-6–a double-edged sword for osteoarthritis (OA)
CN102417921A (en) Bilirubin interference resistant uricase method determination reagent and use method thereof
Matusiewicz et al. Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis?
WO2022095576A1 (en) NOVEL N-ACETYL-β-D GLUCOSAMINIDASE DETECTION AGENT
CN104198473A (en) Stable uric acid detection kit
US20170088894A1 (en) Methods of Predicting Acute Rejection Outcomes
CN101571537A (en) Enzymic measuring reagent of alpha-L-fucosidase resistant to heparin interference and using method thereof
Choi Nitric oxide production is increased in patients with rheumatoid arthritis but does not correlate with laboratory parameters of disease activity
Reznichenko et al. Uromodulin in renal transplant recipients: elevated urinary levels and bimodal association with graft failure
Lobetti Changes in the serum urea: Creatinine ratio in dogs with babesiosis, haemolytic anaemia, and experimental haemoglobinaemia
CN111826417A (en) N-acetyl-beta-D-glucosaminidase detection kit with good stability, preparation method and application
Amin et al. Kidney and urinary tract disorders
Temel et al. Determination of dynamic thiol/disulphide homeostasis in children with tetralogy of Fallot and ventricular septal defect
El-Sammak et al. Elevated plasma homocysteine is positively associated with age independent of C677T mutation of the methylenetetrahydrofolate reductase gene in selected Egyptian subjects
US20100209941A1 (en) Method, device and kit for determining conditions related to a dysfunction of the renal proximal tubule
Uzun et al. Diagnostic value of uric acid to differentiate transudates and exudates
Kisheva et al. Galectin-3 in patients with atrial fibrillation and restored sinus rhythm

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120418